



ORIGINAL ARTICLE

## Dengue fever and prognostic utility of inflammatory markers.

Syed Muhammad Kashif<sup>1</sup>, Zunaira Nawaz<sup>2</sup>, Darshan Kumar<sup>3</sup>, Zill-e-Huma<sup>4</sup>, Gul Anum<sup>5</sup>, Rashid Qadeer<sup>6</sup>

**Article Citation:** Kashif SM, Nawaz Z, Kumar D, Zill-e-Huma, Anum G, Qadeer R. Dengue fever and prognostic utility of inflammatory markers. Professional Med J 2024; 31(08):1188-1194. <https://doi.org/10.29309/TPMJ/2024.31.08.8172>

**ABSTRACT... Objective:** To determine presence of inflammatory markers i.e. hyper-ferritinemia, elevated lactate dehydrogenase, and liver enzymes in dengue fever and their correlation with different classes of dengue severity, defined by new WHO classification. **Study Design:** Cross-sectional Analytical study. **Setting:** Medical Department of Dr. Ruth KM Pfau Civil Hospital Karachi. **Period:** October 2022 to March 2023. **Methods:** Conducted in confirmed cases of Dengue fever, after consent all patients were categorized in three i.e. D-W, D+W and SDF groups. **Results:** 120 patients were included in study. 24 suffered from Severe Dengue Fever (SDF) whereas 28 were in Dengue without warning signs (D-W) group and 68 were in Dengue with warning signs (D+W) group. We found a significant association between liver enzymes (SGPT and SGOT) and dengue severity. SGOT was significantly increased in cases with SDF as compared to D-W and D+W cases (p-value = 0.002). Similarly, ferritin was significantly increased in SDF cases compared to non-severe cohort (p-value <0.001). Using the area under the curve (AUC) of ROC curve, ferritin level (cutoff value of 800), produced a sensitivity of 75% for severe dengue fever. Mean length of stay in patients with non-severe dengue group was 3.63 days vs. 4.3 days in those with SDF (P value 0.002). **Conclusion:** As dengue is becoming a huge burden especially in developing countries, need to take proper measures to establish disease severity and according to severity resource allocation is cornerstone. Significant higher ferritin levels in severe dengue fever than other dengue groups, observed in our study, making serum ferritin a surrogate marker for dengue to predict the severity of dengue fever.

**Key words:** Dengue Without Warning Signs, Dengue with Warning Signs, Ferritin, Lactate Dehydrogenase, Liver Enzymes (SGPT, SGOT), Severe Dengue Fever.

### INTRODUCTION

Dengue virus (DENV) being transmitted in humans by bite of female mosquito *Aedes Aegypti*, is a member of the Flaviviridae family; positive-stranded RNA virus. It has four serotypes, DENV 1-4, that are each antigenically different.<sup>1</sup> Approximately 390 million people worldwide are being infected via this virus every year and billions are at risk of contracting the disease.<sup>2</sup> It is an acute febrile illness that usually presents with fever, muscle pain, body ache, and vomiting. This infection can range from mild dengue fever (DF) to dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Dengue infection's clinical course can be divided into three phases are febrile phase, critical, and recovery phase. In 2009, WHO proposed new categorization for dengue fever i.e. dengue without warning sign,

dengue with warning sign and severe dengue.<sup>3</sup> A history of a prior infection with one of the four serotypes significantly raises the risk of developing severe dengue. However, the pathogenesis of severe dengue is attributed to a non-neutralizing antibody-dependent enhancement (ADE) in secondary dengue infection and cytokine dysregulation.<sup>4</sup>

Pakistan has a population of more than 216.5 million people, making it the fifth most populous country in the world. Dengue cases first appeared in Pakistan in 1994, but didn't receive much attention until the mid-2000s, when they started to increase dramatically and led to its outbreak in the coastal metropolis of Karachi.<sup>5</sup> Pakistan's tropical and subtropical regions are where the dengue virus is found because of favorable

1. MBBS, FCPS, Associate Professor, DUHS.  
2. MBBS, FCPS, Assistant Professor, DUHS.  
3. MBBS, FCPS, Professor, DUHS.  
4. MBBS, FCPS, Assistant Professor, DUHS.  
5. MBBS, FCPS, Senior Registrar, DUHS.  
6. MBBS, FCPS, Professor, DUHS.

**Correspondence Address:**  
Dr. Zunaira Nawaz  
DUHS.  
[zunaira.nawaz@duhs.edu.pk](mailto:zunaira.nawaz@duhs.edu.pk)

**Article received on:** 04/03/2024  
**Accepted for publication:** 22/05/2024

environmental factors, such as rainfall and average maximum temperature.<sup>6</sup> In Pakistan, the monsoon season brings heavy rains and a rise in dengue cases.<sup>7</sup> Floods make this situation worse as it strike the country almost every year due to heavy rain and land sliding.

It is well known that genetics and nutritional status of host and viral-related variables all interact and contribute in severe clinical dengue fever.<sup>8</sup> According to the WHO recommendations regarding dengue, it's important to keep strict vigilance for warning signs such as prolonged vomiting, abdominal pain, lethargy or restlessness, irritability, giddiness, and oliguria.<sup>3</sup> It's incredibly difficult to predict severity of dengue outcomes because these clinical warning symptoms don't show up until late in the illness.<sup>3,9</sup> The WHO recommended that patient with any warning sign should be hospitalized and managed under strict observation. Therefore, identification of risk factors and biomarkers to predict severity and prognosis is crucial as timely measures could be taken for immediate care and intervention can be taken to halt potentially fatal complications.

Like any other disease, dengue has biomarkers that could be used to recognize infection and serve as road map for underlying on going pathological processes, or gauge the severity of infection. These biomarkers include: hematocrit (hct), platelet count, white blood cell (WBC), serum albumin, and hepatic enzymes. However, there is currently a dearth of information available regarding authentic biomarkers those can guide clinicians to predict severity and course of dengue fever. Since acute-phase reactant have been the subject of extensive research in humans, particularly as indicators of disease<sup>10</sup>, it is vital to confirm the presence of certain acute-phase proteins in samples from cohorts where dengue is an endemic disease. In this study, our main purpose is to propose the potential biomarkers that can predict the prognostic utility in dengue fever, we are assessing biomarkers such as serum ferritin, LDH, and liver enzymes in patients with severe dengue and compare them with non-severe dengue. So that any potential biomarkers could be established to predict severity of

dengue in any individual patient and we can take measures prior to storm of complications.

## OBJECTIVES

1. To document levels of Ferritin, LDH and Liver enzymes (SGPT and SGOT) in WHO proposed categories of Dengue fever.
2. To document association of these biomarkers with severity of dengue infection.
3. To document prognostic utility of these biomarkers in dengue fever.

## METHODS

A cross-sectional, Prospective analytical study, conducted in medical department of Dr. Ruth KM Pfau Civil Hospital Karachi, from October 2022 to March 2023 after approval by the Institutional Review Board (IRB) Committee of Dow University of Health Sciences (IRB-2679/DUHS/Approval/2022/1061).

Consecutive, non-probability sampling technique was used, sample size was calculated using WHO sample size calculator, keeping 13% population prevalence of severe dengue in southeast Asia<sup>11</sup>, 95% confidence interval and 6% precision, minimum sample size came out was 120.

## DATA COLLECTION

Individuals 18 years and above, with recent fever of  $\leq$  seven days and positive dengue profile either Dengue NS1 antigen or Dengue IgM antibody, were included in the study after informed written consent. Dengue patients with other co-morbidities like CKD, CLD, auto-immune illness and other immune-compromised illness, patient taking steroids or immune-modulators or with history of recent blood transfusion were excluded from the study.

All participants were categorized, into three categories, based on the modified WHO classification 2009, "dengue without warning signs (D-W), dengue with warning signs (D+W) and severe dengue fever (SDF)"<sup>3</sup>, depending on participant's clinical presentation. 10 ml Blood sample drawn for CBC, CRP, Serum ferritin, LDH and liver enzyme (SGPT, SGOT) by a professional phlebotomist.

## Operational Definition

“New World Health Organization (WHO) classifications of dengue (2009).<sup>3</sup>

### 1. Dengue without warning signs: (D-W)

Fever and two of the following:

Nausea, vomiting, Rash, Aches and pains, Leukopenia, Positive tourniquet test

Laboratory confirmed dengue. With ability:

- To tolerate adequate volumes of oral fluid replacement
- To pass urine at least once every 6 hours

### 2. Dengue with warning signs (D+W)

Patients with any of the following features:

-At least one of the following warning signs:

Abdominal pain or tenderness, Persistent vomiting, Clinical fluid accumulation, Mucosal bleed (gingival bleeding, epistaxis, conjunctival bleeding, hematemesis, melena, freshblood per rectum, hematuria, or vaginal bleeding), Lethargy/restlessness, Liver enlargement >2 cm, Increased Htc with concurrent decrease in platelet count ( $\leq 100,000$  platelets/mm<sup>3</sup>).

OR

-At least one comorbid condition such as:

- Pregnancy or Infancy or Old age or Diabetes mellitus or Renal failure

OR

-Social circumstances such as

- Living alone or Living far from hospital

### 3. Severe Dengue fever (SDF)

Patients with any of the following features:

-Severe plasma leakage leading to:

- Shock or Fluid accumulation leading to respiratory distress

-Severe bleeding as evaluated by clinician

-Severe organ involvement:

- Liver: AsT or ALT  $> = 1000$  IU/L
- CNS: impaired consciousness.”

## DATA ANALYSIS

The quantitative variables expressed as mean and standard deviation whereas qualitative variables expressed as frequencies and percentages. Chi-square test was used to calculate the correlation between variables. One-way analysis of variance (ANOVA) used as the statistical test of significance to compare each parameter with different severity groups. The receiver operating

characteristic (ROC) curve, used to determine, ferritin and LDH cutoff values for severe and non-severe dengue groups, as well as the test's specificity and sensitivity. AUC values between 0.5 and 0.60, 0.6 to 70, 0.7 to 80, 0.8 to 90, and 0.90 to 1.00 were categorized as failing, bad, fair, good, and excellent, respectively. The level of statistical significance set as p-value  $< 0.05$ . 2-tailed hypothesis testing used. SPSS software version 23.0 was used to perform the analysis.

## RESULTS

120 patients were included in study. 24 suffered from Severe Dengue Fever (SDF) whereas 28 were in Dengue without warning signs (D-W) group and 68 were in Dengue with warning signs (D+W) group. We found a significant association between liver enzymes (SGPT and SGOT) and dengue severity. SGOT was significantly increased in cases with SDF as compared to D-W and D+W cases (p-value = 0.002). Similarly, ferritin was significantly increased in SDF cases compared to non-severe cohort (p-value  $< 0.001$ ). Using the area under the curve (AUC) of ROC curve, ferritin level (cutoff value of 800), produced a sensitivity of 75% for severe dengue fever. Mean length of stay in patients with non-severe dengue group was 3.63 days vs. 4.3 days in those with SDF (P value 0.002).

## DISCUSSION

The symptoms of dengue infection can vary from a self-limiting form to severe multi-organ failure that can cause catastrophic life-threatening conditions such as plasma leakage, hemorrhage, or other serious complications. The prevalence of dengue fever among adults in South-East Asia has significantly increased recently, leading to an increase in hospitalizations and associated costs.<sup>12</sup> Researchers are looking into several clinical profiles and the development of a number of biochemical markers in this sickness, so that promptly disease can be controlled and treated to mitigate risk of complications.

The prevalence of dengue fever in men was 80/120, 66.6% in this study, while a larger percentage of men had D+W symptoms (60/68, 88%).

| Disease Severity                 | Dengue Without Warning Sign (D-W) (n=28) |      | Dengue With Warning Sign (D+W) (n=68) |      | Severe Dengue Fever (SDF) (n=24) |     | Pearson Chi-Square |
|----------------------------------|--|------|---------------------------------------|------|----------------------------------|-----|--------------------|
|                                  | N  | %    | N                                     | %    | N                                | %   | P-Value            |
| Age (years) median ±SD           | 20±9.2                                   |      | 23±10.5                               |      | 28.5±10.5                        |     | <0.001             |
| <b>Gender</b>                    |  |      |                                       |      |                                  |     | <0.001             |
| Male                             | 8  | 28.5 | 60                                    | 88   | 12                               | 50  |                    |
| Addiction                        | 0  |      | 12                                    | 18   | 8                                | 33  | 0.001              |
| Comorbids                        | 0  |      | 16                                    | 23.5 | 8                                | 33  | <0.001             |
| <b>Clinical features</b>         |  |      |                                       |      |                                  |     |                    |
| Body ache                        | 24                                       | 86   | 60                                    | 88   | 24                               | 100 | 0.005              |
| <b>Bleeding</b>                  |  |      |                                       |      |                                  |     | <0.001             |
| Minor Bleeding                   | 0  | 0    | 52                                    | 76   | 12                               | 50  |                    |
| Major bleeding                   | 0  | 0    | 0                                     | 0    | 12                               | 50  |                    |
| Abdominal pain                   | 20                                       | 71   | 60                                    | 88   | 24                               | 100 | 0.003              |
| Loose motions                    | 8  | 28.5 | 20                                    | 29   | 4                                | 17  | 0.463              |
| Vomiting                         | 12                                       | 43   | 52                                    | 76   | 16                               | 67  | 0.008              |
| Petechiae                        | 12                                       | 43   | 64                                    | 100  | 24                               | 100 | <0.001             |
| Ascites                          | 4  | 14   | 16                                    | 23.5 | 12                               | 50  | 0.01               |
| Pleural effusion                 | 4  | 14   | 12                                    | 18   | 12                               | 50  | 0.005              |
| Hospital stay of more than 3days | 8  | 28.5 | 64                                    | 100  | 24                               | 100 | <0.001             |

**Table-I. Baseline demographic details and characteristics of Dengue patients with respect to disease severity**

| Disease Severity             | Dengue Without Warning Sign ( D-W) |                   | Dengue With Warning Signs (D+W) |                   | Severe Dengue Fever (SDF) |                   | P-Value |
|------------------------------|------------------------------------|-------------------|---------------------------------|-------------------|---------------------------|-------------------|---------|
|                              | Mean± SD                           | Median (IQ Range) | Mean± SD                        | Median (IQ Range) | Mean± SD                  | Median (IQ Range) |         |
| <b>Hematological markers</b> |                                    |                   |                                 |                   |                           |                   |         |
| Hemoglobin (g/dl)            | 11.2(2.0)                          | 12(3.7)           | 14.2(1.99)                      | 14(2)             | 12.1(1.09)                | 12(2)             | <0.001  |
| Absolute Neutrophil count    | 3505(2134)                         | 2100(4336)        | 2549(1559)                      | 2400(700)         | 2754(1444)                | 2512(1900)        | 0.114   |
| Absolute Lymphocytets count  | 1880(760)                          | 1800(1400)        | 1885(1067)                      | 1680(1240)        | 2816(2235)                | 1730(1760)        | 0.150   |
| Platelet count Day1          | 126(90)                            | 119(186)          | 64.4(92)                        | 35(42)            | 24(18)                    | 18(17)            | <0.001  |
| Platelet count Day3          | 110(64)                            | 94(146)           | 79(59)                          | 57(52)            | 60(37)                    | 46(69)            | 0.004   |
| CRP(mg/dl)                   | 9.6(9.8)                           | 4(19.7)           | 7.5(9.4)                        | 4(3.1)            | 14.8(18.4)                | 7.2(13.6)         | 0.155   |
| SGPT(IU/l)                   | 53(44)                             | 41(42)            | 98(63)                          | 74(58)            | 367(374)                  | 252(270)          | <0.001  |
| SGOT(IU/l)                   | 117(118)                           | 84(85)            | 148(105)                        | 94()              | 505(285)                  | 428()             | <0.001  |
| Ferritin(ng/ml)              | 1203(2704)                         | 150(71)           | 1854(1191)                      | 1400(1682)        | 8040(9269)                | 4850(1429)        | 0.006   |
| LDH(IU/l)                    | 367(208)                           | 357(160)          | 388(108)                        | 380(166)          | 761(448)                  | 640(315)          | 0.001   |

**Table-II. Hematological and Biochemical parameters of Dengue patients with respect to Disease Severity**

Analysis of mean (robust Welch’s test) and variance between non-severe and severe Dengue patients. (p-value less than 0.05)

|          | AUC [IC=95%] | Cut-off value | Sensitivity [IC=95%] | Specificity [IC=95%] | PPV [IC=95%] | NPV [IC=95%] |
|----------|--------------|---------------|----------------------|----------------------|--------------|--------------|
| CRP      | 0.62         | 5.9           | 66%                  | 71%                  | 25.38%       | 93.32%       |
| LDH      | 0.87         | 427           | 83%                  | 71%                  | 29.96%       | 96.55%       |
| Ferritin | 0.85         | 2170          | 83%                  | 73%                  | 31.48%       | 96.64%       |
| SGPT     | 0.80         | 95            | 83%                  | 71%                  | 29.96%       | 96.55%       |
| SGOT     | 0.91         | 143           | 83%                  | 71%                  | 29.96%       | 96.55%       |

**Table-III. Diagnostic performance of continuous variables and cut-off value**

Deshkar et al. likewise found this to be the case in his study.<sup>13</sup> According to a Pakistani research, men make up roughly 68.6% of the population.<sup>14</sup> One explanation for why young men are more affected could be that they are more susceptible to infection due to their outside work. Another claim makes the case that female immune responses are stronger than those of males, which leads to more cytokines being produced and, ultimately, greater resistance to dengue infection. The average age of dengue fever patients in our study was 27 years (SD=10), roughly, and there was a similar pattern of age group being influenced in many other Indian studies as well.<sup>13</sup>

Similar to what Khan et al. had noticed, the three most frequent symptoms in our study were bodyache (90%) abdominal discomfort (86.7%) and vomiting (66.7%).<sup>15,16</sup> In our study, 83.3% of dengue patients had petechial rash, which is comparable to the finding made by Itoda et al.<sup>17</sup> Pleural effusion and ascites were observed in (26.7%) and (23.3%), respectively. Major bleeding was only reported in ten (10) percent of patients, but minor bleeding was seen in 53.3 percent of patients. In cases of severe dengue fever, petechial rash, fluid third spacing, and bleeding were more frequent.

The reticuloendothelial system of our bodies is harmed by dengue virus. Ferritin and lactate dehydrogenase (LDH) are indicators of multi-organ damage and reticuloendothelial system activation. Although dengue is a non-hepatotropic virus, hepatic enzyme dysregulation is frequently seen, since the liver is a crucial component of the reticuloendothelial system. In general, AST levels are more affected than ALT levels.<sup>18,19,20</sup>

According to table 2, severe dengue patients had median serum ferritin levels 4850 g/dl (IQR=14290), that was significantly high than non-severe cases. Our results are in line with those of other studies<sup>21</sup>, that found ferritin to be a reliable biomarker for predicting severe dengue. With an area under the curve (AUC) of 0.863, a standard error (SE) of 0.043, a 95% confidence interval (CI) of 0.778 to 0.947, and a cut-off level of 2170, serum ferritin level was a “good” predictor

of severe dengue in our study. This predictor had an 83% sensitivity and 73% specificity for diagnosing severe dengue.

LDH, another biomarker assessed in our study for predicting severe dengue with an AUC of 0.87 turned out to be a significant biomarker. Although there was no statistical significant difference found in Ldh levels between non-severe without warning sign (D-W) and non-severe with warning (D+W) sign groups (p-value 0.879), but a statistical significant difference identified between non-severe with warning (D+W) signs and severe dengue fever (SDF) (p-value 0.001).

In contrast to previous studies, our study found CRP, not a reliable indicator of dengue severity.<sup>22</sup> The CRP level did not significantly differ between the D-W, D+W, and SDF groups (p-value 0.155), making it an ineffective marker in this study for determining severity of dengue infection.

With an area under the curve (AUC) of 0.91 and a cut-off level of 143, SGOT was a “very-good” predictor of severe dengue in this research, therefore making hepatic impairment a well-known aspect of dengue infection. SGOT had an 83% sensitivity and 73% specificity for identifying severe dengue. Similar results were found in other old researches.<sup>23</sup> Raised aminotransferases were also noted by Souza et al.<sup>24</sup> who discovered that AST levels were higher than ALT levels in their study.

Limitations: The participants included were from single-center and all were in-patient or hospitalized. Inflammatory markers were only evaluated on the first day of hospitalization; correlations with severity were not determined by serial measurements. A large sample size, several locations, and repeated testing of all inflammatory markers should be done in order to generalize, further implement and clearly demonstrate the results.

## CONCLUSION

In people suffering and hospitalized due to dengue infection, our study revealed number of clinical variables that were each individually attributed to the emergence of severe dengue. In



order to lower morbidity and mortality, this can help in the early identification and timely therapy of individuals who are at risk. In our study, we explored that severe dengue fever patients had significantly higher serum ferritin levels than other dengue groups, making serum ferritin a surrogate marker for dengue to predict the severity of dengue fever infection.

### CONFLICT OF INTEREST

The authors declare no conflict of interest.

### SOURCE OF FUNDING

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.







Copyright© 22 May, 2024.

### REFERENCES

1. St. John AL, Rathore AP. **Adaptive immune responses to primary and secondary dengue virus infections.** *Nature Reviews Immunology.* 2019 Apr; 19(4):218-30.
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. **The global distribution and burden of dengue.** *Nature.* 2013 Apr 25; 496(7446):504-7.
3. World Health Organization, Special Programme for Research, Training in Tropical Diseases, World Health Organization. **Department of control of neglected tropical diseases, world health organization.** Epidemic, Pandemic Alert. **Dengue: guidelines for diagnosis, treatment, prevention and control.** World Health Organization; 2009.
4. Halstead S, Wilder-Smith A. **Severe dengue in travellers: Pathogenesis, risk and clinical management.** *J Travel Med.* 2019 Oct 14; 26(7):taz062. doi: 10.1093/jtm/taz062. PMID: 31423536.
5. Jahan F. **Dengue fever (DF) in Pakistan.** *Asia Pacific Family Medicine.* 2011 Dec; 10:1-4.
6. Shabbir W, Pilz J, Naeem A. **A spatial-temporal study for the spread of dengue depending on climate factors in Pakistan (2006–2017).** *BMC Public Health.* 2020 Dec; 20(1):1-0.
7. Ahmad S, Aziz MA, Aftab A, Ullah Z, Ahmad MI, Mustan A. **Epidemiology of dengue in Pakistan, present prevalence and guidelines for future control.** *Int J Mosq Res.* 2017; 4(6):25-32.
8. Martina BE, Koraka P, Osterhaus AD. **Dengue virus pathogenesis: An integrated view.** *Clinical Microbiology Reviews.* 2009 Oct; 22(4):564-81.
9. Leo YS, Gan VC, Ng EL, Hao Y, Ng LC, Pok KY, et al. **Utility of warning signs in guiding admission and predicting severe disease in adult dengue.** *BMC Infectious Diseases.* 2013 Dec; 13(1):1-7.
10. Endre ZH, Westhuyzen J. **Early detection of acute kidney injury: Emerging new biomarkers.** *Nephrology.* 2008 Mar; 13(2):91-8.
11. Rosenberger KD, Alexander N, Martinez E, Lum LCS, Dempfle CE, Junghanss T, et al. **DENCO Clinical Study Group. Severe dengue categories as research endpoints-Results from a prospective observational study in hospitalized dengue patients.** *PLoS Negl Trop Dis.* 2020 Mar 4; 14(3):e0008076. doi: 10.1371/journal.pntd.0008076. PMID: 32130212; PMCID: PMC7055818.
12. Garg P, Nagpal J, Khairnar P, Seneviratne SL. **Economic burden of dengue infections in India.** *Transactions of the Royal Society of Tropical Medicine and Hygiene.* 2008 Jun 1; 102(6):570-7.
13. Deshkar ST, Raut SS, Khadse RK. **Dengue infection in central India: A 5 years study at a tertiary care hospital.** *Int J Res Med Sci.* 2017 Jun; 5(6):2483-9.
14. Khan J, Khan A. **Incidence of dengue in 2013: Dengue outbreak in District Swat, Khyber Pakhtunkhwa, Pakistan.** *Inter J of Fauna and Biolo Stud.* 2015; 2(1):1-7.
15. KhanE, Siddiqui J, Shakoor S, Mehraj V, Jamil B, Hasan R. **Dengue outbreak in Karachi, Pakistan, 2006: Experience at a tertiary care center.** *Trans R Soc Trop Med Hyg.* 2007; 101(11): 1114-19.
16. Pan ST, Su PA, Chen KT, Lin HJ, Lai WP. **Comparison of the clinical manifestations exhibited by dengue and non-dengue patients among children in a medical center in southern Taiwan.** *J Acute Med.* 2014; 4(2): 53-56.
17. Itoda I, Masuda G, Suganuma A, Imamura A, Ajisawa A, Yamada K, et al. **Clinical features of 62 imported cases of dengue fever in Japan.** *Am J Trop Med Hyg.* 2006; 75:470-474.
18. Seneviratne SL, Malavige GN, De Silva HJ. **Pathogenesis of liver involvement during dengue viral infections.** *Transactions of the Royal Society of Tropical Medicine and Hygiene.* 2006 Jul 1; 100(7):608-14.
19. Mohan B, Patwari A, Anand V. **Brief report. Hepatic dysfunction in childhood dengue infection.** *J Trop Pediatr.* 2000; 46:40-3.

20. Uchadadia S, Ghodke B, Bhuta K, Kejriwal A, Ghanekar J. **“Degree of impairment of liver function in dengue fever correlates to the severity of its complications.”** Journal of the Medical Sciences. 2015; 115-119.
21. Suresh SC, Hanumanthaiah R, Ramakrishna C, Sandeep R, Narasimhasetty PS, Ramakrishna V, et al. **Serum ferritin as a prognostic indicator in adult dengue patients.** The American Journal of Tropical Medicine and Hygiene. 2021 Mar; 104(3):1072.
22. Rao R, Nayak S, Pandey AK, Kamath SU. **Diagnostic performance of C-reactive protein level and its role as a potential biomarker of severe dengue in adults.** Asian Pacific Journal of Tropical Medicine. 2020 Aug 1; 13(8):358.
23. Ahmed A, Alvi AH, Butt A, Nawaz AA, Hanif A. **Assessment of dengue fever severity through liver function tests.** J Coll Physicians Surg Pak. 2014 Sep 1; 24(9):640-4.
24. Souza LJ, Alves JG, Nogueira RM, Gicovate Neto C, Bastos DA, Siqueira EW, et al. **Aminotransferase changes and acute hepatitis in patients with dengue fever: Analysis of 1,585 cases.** Brazilian Journal of Infectious Diseases. 2004; 8:156-63.

### AUTHORSHIP AND CONTRIBUTION DECLARATION

| No. | Author(s) Full Name  | Contribution to the paper  | Author(s) Signature   |
|-----|----------------------|--|---|
| 1   | Syed Muhammad Kashif | Conception & design, supervision.                                    |  |
| 2   | Zunaira Nawaz        | Supervision, Analysis & interpretation, writing and critical review. |  |
| 3   | Darshan Kumar        | Design, Supervision & critical review.                               |  |
| 4   | Zill-e-Huma          | Data collection and literature review.                               |  |
| 5   | Gul Anum             | Data collection, Analysis and literature review.                     |  |
| 6   | Rashid Qadeer        | Conception, design and supervision, Critical review.                 |  |